In this issue of Indian Journal of ophthalmology, Chakraborty et al share their experience of using Brolucizumab in polypoidal choroidal vasculopathy (PCV).[1] Considering the recent introduction of this drug in the growing armamentarium against retinal vascular diseases, this article is important both in terms of efficacy in this relatively less common disease as well as to assure us that the risk of post injection inflammation is small to negligible - at least in this small series of 21 eyes. The report itself has all the trappings of a retrospective study with lack of controls.It is impressive that the mean injection free interval was 12 weeks in this study of eyes that failed with other anti VEGF drugs. This appears to be a good indicator of the potential for use of Brolucizumab for non-responders of PCV. It is also good to see that both sub-retinal fluid and intra retinal fluid dried up totally in roughly 50% of the eyes. The lack of inflammation or any other adverse events in this small series is also welcome.The only issue I wish to raise is the doubt with respect to the case shown in Fig. 1. The fluorescein angiogram suggests multifocal central serous retinopathy (CSR) with definite CSR leaks along upper arcade and nasal to disc. The autofluorescence also has tell-tale tracking. The indocyanine green (ICG) picture displayed does not have convincing polyps or branching vascular network. The only feature in favour of PCV is the sharp pigment epithelial detachment (PED) temporal to macula. The pachychoroid, sub macular fibrosis and macular atrophy are non-specific and could be seen with both PCV as well as chronic multifocal CSR. However, this does not in any way interfere with the inference on efficacy of Brolucizumab.